Literature DB >> 22292348

Evidence-based guidelines for evaluation and antimicrobial therapy for common emergency department infections.

Denise Nassisi1, Marisa L Oishi.   

Abstract

Infections are among the most common diagnoses in the emergency department (ED), and antibiotics are among the most frequently prescribed drugs. Community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP) are frequently encountered in the ED, and pneumonia is the seventh leading cause of death in the United States. Cystitis, pyelonephritis, and complicated urinary tract infection (UTI) are often treated in the ED, with UTI being one of the most common reasons for healthy young women to require antimicrobial treatment. Intra-abdominal infections have an incidence of 3.5 million cases per year in the United States, and emergency clinicians must make complex decisions regarding appropriate evaluation and management. Skin and soft-tissue infections (SSTIs) are common, their incidence in the ED has been rising, and the emergence of methicillin-resistant Staphylococcus aureus (MRSA) infection has altered their management. Timely diagnosis and management of infectious disease, including proper antimicrobial treatment, is an important goal of emergency care. This issue of Emergency Medicine Practice reviews the available evidence and consensus guidelines for the management of common infectious diseases presenting to the ED and presents recommendations for treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22292348

Source DB:  PubMed          Journal:  Emerg Med Pract        ISSN: 1524-1971


  1 in total

1.  Impact of Outpatient vs Inpatient ABSSSI Treatment on Outcomes: A Retrospective Observational Analysis of Medical Charts Across US Emergency Departments.

Authors:  P Brandon Bookstaver; Timothy C Jenkins; Edward Stenehjem; Shira Doron; Jack Brown; Shannon H Goldwater; Carlos Lopes; Angela Haynes; Chuka Udeze; Yifan Mo; Patrick Gillard; Yan Liu; Katelyn Keyloun
Journal:  Open Forum Infect Dis       Date:  2018-05-15       Impact factor: 3.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.